Eliem Therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. Headquartered in Seattle with R&D primarily in Cambridge, UK, Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. Eliem is a publicly traded company (NASDAQ: ELYM) Read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/